HCV Next March Issue: Chasing the ‘Holy Grail’of Ever-Shortening Regimens

Hello everyone, over at Healio the March 2015 print edition of "HCV Next" is ready for your viewing pleasure.

"HCV Next" offers information on a range of topics, which include diagnosis, transmission, new combination therapies, side effects, drug/drug interaction, guidelines, fatty liver disease and more.

This month the focus is on shortening HCV treatment duration...

Breaking the 12-Week Barrier: The Search for Shorter Treatment Duration in HCV Therapy

Despite vastly improved sustained virologic response rates with 12 weeks of newer therapies, researchers have continuously worked for shorter, still effective treatment windows, believing that a cure obtained in 4 or 6 weeks would lighten the load of adherence and cost placed on patients with hepatitis C virus. .

Table of Contents

Commentary

Chasing the ‘Holy Grail’of Ever-Shortening Regimens

5 Questions

A Conversation with Andrew J. Muir, MD, MHS

Cover Story

Breaking the 12-Week Barrier: The Search for Shorter Treatment Duration in HCV Therapy

Feature

The Dangers of HCV Transmission: How the Infection Spreads Today

HCV Rx

Targeting the HCV Genome: A Four-Drug Fixed-Dose Regimen

In the Journals

Interferon-Free Regimen well Tolerated in HIV/HCV Coinfected Patients

HCV Mortality Rates Unchanged or Increased Across Three Regions

Pediatric HCV

Setting Things Straight: How to Counsel Parents of HCV-Infected Children

Trend Watch

Two HCV Treatments Lose Breakthrough Therapy Designation

CDC, Quest Collaborate to Better Screen, Treat and Reduce Hepatitis

Boceprevir Expected to be Discontinued by December 2015

RG-101 Monotherapy Reduced Viral Loads in Patients with HCV

HCV Regimen Candidate Licensed by International Pharmaceutical Company

Begin here....